194 related articles for article (PubMed ID: 9058626)
1. Soluble intercellular adhesion molecule-1 in primary biliary cirrhosis: effect of ursodeoxycholic acid and immunosuppressive therapy.
Lim AG; Wolfhagen FH; Verma A; van Buuren HR; Jazrawi RP; Levy JH; Northfield TC; Schalm SW
Eur J Gastroenterol Hepatol; 1997 Feb; 9(2):155-61. PubMed ID: 9058626
[TBL] [Abstract][Full Text] [Related]
2. Bile acid therapy and markers of immune-mediated damage in primary biliary cirrhosis.
de Caestecker JS
Eur J Gastroenterol Hepatol; 1997 Feb; 9(2):145-7. PubMed ID: 9058624
[TBL] [Abstract][Full Text] [Related]
3. Triple therapy with ursodeoxycholic acid, prednisone and azathioprine in primary biliary cirrhosis: a 1-year randomized, placebo-controlled study.
Wolfhagen FH; van Hoogstraten HJ; van Buuren HR; van Berge-Henegouwen GP; ten Kate FJ; Hop WC; van der Hoek EW; Kerbert MJ; van Lijf HH; den Ouden JW; Smit AM; de Vries RA; van Zanten RA; Schalm SW
J Hepatol; 1998 Nov; 29(5):736-42. PubMed ID: 9833911
[TBL] [Abstract][Full Text] [Related]
4. Serum interferon gamma in primary biliary cirrhosis: effect of ursodeoxycholic acid and prednisone therapy alone and in combination.
Fracchia M; Secreto P; Tabone M; Zaffino C; Pera A; Galatola G
Eur J Gastroenterol Hepatol; 2000 Apr; 12(4):463-8. PubMed ID: 10784002
[TBL] [Abstract][Full Text] [Related]
5. Development of autoimmune hepatitis in primary biliary cirrhosis.
Gossard AA; Lindor KD
Liver Int; 2007 Oct; 27(8):1086-90. PubMed ID: 17845536
[TBL] [Abstract][Full Text] [Related]
6. [Primary biliary cirrhosis].
Corpechot C
Gastroenterol Clin Biol; 2003 Mar; 27(3 Pt 1):320-4. PubMed ID: 12700520
[No Abstract] [Full Text] [Related]
7. Increased intercellular adhesion molecule-1 serum concentration in cholestasis.
Polzien F; Ramadori G
J Hepatol; 1996 Dec; 25(6):877-86. PubMed ID: 9007716
[TBL] [Abstract][Full Text] [Related]
8. Case-control study on prednisolone combined with ursodeoxycholic acid and azathioprine in pure primary biliary cirrhosis with high levels of immunoglobulin G and transaminases: efficacy and safety analysis.
Fang YQ; Lv DX; Jia W; Li J; Deng YQ; Wang Y; Yu M; Wang GQ
Medicine (Baltimore); 2014 Oct; 93(20):e104. PubMed ID: 25365404
[TBL] [Abstract][Full Text] [Related]
9. Clinical and biochemical features and therapy responses in primary biliary cirrhosis and primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Günsar F; Akarca US; Ersöz G; Karasu Z; Yüce G; Batur Y
Hepatogastroenterology; 2002; 49(47):1195-200. PubMed ID: 12239904
[TBL] [Abstract][Full Text] [Related]
10. [Primary biliary cirrhosis and autoimmune hepatitis overlap syndrome: therapeutic features in 5 patients].
Cheikh I; Said Y; Chaabouni H; Ouerghi H; Ben Ammar A
Ann Med Interne (Paris); 2003 Feb; 154(1):7-11. PubMed ID: 12746654
[TBL] [Abstract][Full Text] [Related]
11. Management of autoimmune and cholestatic liver disorders.
Krok KL; Munoz SJ
Clin Liver Dis; 2009 May; 13(2):295-316. PubMed ID: 19442920
[TBL] [Abstract][Full Text] [Related]
12. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
Holtmeier J; Leuschner U
Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
[TBL] [Abstract][Full Text] [Related]
13. The combination of ursodeoxycholic acid and methotrexate for primary biliary cirrhosis is not better than ursodeoxycholic acid alone.
González-Koch A; Brahm J; Antezana C; Smok G; Cumsille MA
J Hepatol; 1997 Jul; 27(1):143-9. PubMed ID: 9252088
[TBL] [Abstract][Full Text] [Related]
14. Autoimmune liver disease. Current standards, future directions.
Gish RG; Mason A
Clin Liver Dis; 2001 May; 5(2):287-314. PubMed ID: 11385965
[TBL] [Abstract][Full Text] [Related]
15. Reversal of cirrhosis in a patient with primary biliary cirrhosis-autoimmune hepatitis overlap syndrome.
Vallone TM; Ditelberg J; Kaplan MM
Dig Dis Sci; 2005 Jan; 50(1):167-70. PubMed ID: 15712656
[No Abstract] [Full Text] [Related]
16. Ursodeoxycholic acid for primary biliary cirrhosis.
Gluud C; Christensen E
Cochrane Database Syst Rev; 2002; (1):CD000551. PubMed ID: 11869580
[TBL] [Abstract][Full Text] [Related]
17. The use of methotrexate, colchicine, and other immunomodulatory drugs in the treatment of primary biliary cirrhosis.
Kaplan MM
Semin Liver Dis; 1997 May; 17(2):129-36. PubMed ID: 9170200
[TBL] [Abstract][Full Text] [Related]
18. Does ursodeoxycholic acid mediate immunomodulatory and anti-inflammatory effects in patients with primary sclerosing cholangitis?
van Milligen de Wit AW; Kuiper H; Camoglio L; van Bracht J; Jones EA; Tytgat GN; van Deventer SJ
Eur J Gastroenterol Hepatol; 1999 Feb; 11(2):129-36. PubMed ID: 10102223
[TBL] [Abstract][Full Text] [Related]
19. Adjuvant cholylsarcosine during ursodeoxycholic acid treatment of primary biliary cirrhosis.
Ricci P; Hofmann AF; Hagey LR; Jorgensen RA; Rolland Dickson E; Lindor KD
Dig Dis Sci; 1998 Jun; 43(6):1292-5. PubMed ID: 9635620
[TBL] [Abstract][Full Text] [Related]
20. [The overlap syndrome of autoimmune hepatitis and primary biliary cirrhosis. Clinical and therapeutic analysis of 5 cases].
Cheikh I; Said Y; Chaabouni H; Ouerghi H; Ben Ammar A
Tunis Med; 2003 Jul; 81(7):499-504. PubMed ID: 14534962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
